Everyone Launches. Almost No One Lands.

I placed second in a stand-up competition once. I’ve been dining out on that “second” for years, mostly because the lesson underneath it turned out to be worth more than the trophy would have been.

Here’s what I learned about bombing, and occasionally not bombing. Every comic in that lineup could tell a joke. Setup, timing, punchline — table stakes. The ones who won didn’t have better jokes. They found the one thing only they could say to that specific room, and they owned it before anyone else could reach for it.

Launches are the same. And most of them lose for the same reason.

Why Do So Many Pharma Launches Struggle to Differentiate?

Walk into any therapeutic category right now and count the entrants. New mechanisms. New formulations. Once-monthly instead of once-weekly, oral instead of infused. Everyone has a launch. Everyone has a deck that says first-in-class, or best-in-class, or — when both are taken — only-in-class.

And everyone has data. Mountains of it. Competitive intelligence on every rival molecule. Share-of-voice tracking. Positioning studies that map the category on two axes and drop everyone’s dot into a quadrant. You can see the entire crowd.

Seeing the crowd is not the same as knowing where you can win.

This isn’t just a Shapiro+Raj observation. Independent research backs it up: a Deloitte analysis found that nearly half of drug launch underperformance traces back to an inadequate understanding of market and customer needs, with roughly four in ten cases tied directly to poor product differentiation.¹ Separately, McKinsey’s launch research has found that only about a quarter of launches enter the market with genuine differentiation against a high-burden disease² — meaning most brands are competing for the same crowded middle ground the data already shows them.

Why Isn’t “Where You Can Win” a Data Point?

This is the launch question that keeps commercial leaders up at night. Not “what does the market look like” — they have forty slides on that. The question is: where, in that market, can we credibly win, and hold it?

That’s not a data question. It’s an insight question. The data describes the field — it tells you where everyone is standing. It cannot tell you where the open ground is, because open ground isn’t a data point. It’s a judgment: which position is defensible against competitors who will react, believable to customers who’ve heard every claim before, and true to what your asset can actually deliver.

The strongest positioning work connects those two things. It maps the mental territory customers already associate with each brand, identifies genuine whitespace, and then determines whether a proposed position can hold across the settings and customer groups that will decide commercial success.

That distinction matters: a territory can sound compelling in a workshop and still fail when it meets a different treatment context, a less committed prescriber, or a competitor prepared to respond.

Why Does More Competitive Data Make the Problem Worse, Not Better?

More competitive intelligence doesn’t find that position. Past a point it does the opposite — it shows you a field so crowded that every inch looks occupied, until the safe move looks like crowding in beside the leader with a slightly sharper claim. Which is how you launch, and don’t land.

Why Does the Launch Equation Collapse Without Insight?

A launch is where the Insight factor earns its keep. All the competitive data in the world, multiplied by an insight of near-zero — a position anyone could have claimed — collapses to a launch that’s technically sound and commercially invisible. The data was never the problem. The interpretation was.

And speed matters here more than almost anywhere, because the open ground you find is open only until someone stands on it. An insight about where to win, delivered after the competitor’s launch, is a post-mortem.

What Should Commercial Leaders Ask Instead?

So change the question.

Before the next launch, don’t ask what the market looks like. You know what it looks like. Ask the harder thing: where can we credibly win — and would that position survive a competitor who’s paying attention?

That’s the question my team at Shapiro+Raj is built to answer as a life sciences insights consultancy — not to describe the crowd, but to find the room only you can own, and get you there before someone else does. It’s the same discipline behind TechManity™, our approach to pairing AI-driven synthesis with human behavioral science to compress launch strategy timelines without cutting corners on judgment.

Every comic in that lineup could tell a joke. Very few found the room. The launch is no different.

¹ Deloitte, Rethinking Market Access, cited in “Addressing the 58% Launch Failure Rate,” MedCity News.

² McKinsey & Company, “The Secret of Successful Drug Launches.”